SCHEMBL1066869

SCHEMBL1066869

CCOC(=O)/C=C(/C)Oc1cccc(OC)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
PLIN1 O60240 1/20 0.41
POLB P06746 1/20 0.41
PLIN5 Q00G26 1/20 0.41
KMT2A Q03164 1/20 0.41
ABHD5 Q8WTS1 1/20 0.41
ALDH1A1 P00352 2/20 0.39
MAOB P27338 1/20 0.39
TSHR P16473 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
FDPS P14324 1/20 0.37
GPR35 Q9HC97 1/20 0.37
GAA P10253 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1066872 1.00 MAPT (0.41) MAPTLMNAMEN1PLIN1POLB
SCHEMBL1067424 0.89 MAPT (0.38) MAPTLMNAMEN1POLBKMT2A
SCHEMBL1067425 0.89 MAPT (0.38) MAPTLMNAMEN1POLBKMT2A
SCHEMBL1066360 0.88 MAPT (0.47) MAPTLMNAMEN1POLBKMT2A
SCHEMBL1066356 0.88 MAPT (0.47) MAPTLMNAMEN1POLBKMT2A
SCHEMBL1066358 0.88 MAPT (0.47) MAPTLMNAMEN1POLBKMT2A
SCHEMBL1063648 0.86 MAPT (0.48) MAPTLMNAMEN1PLIN1POLB
SCHEMBL1063649 0.86 MAPT (0.48) MAPTLMNAMEN1PLIN1POLB
SCHEMBL1069034 0.85 NFE2L2 (0.46) MAPTLMNAMEN1PLIN1POLB
SCHEMBL1069039 0.85 NFE2L2 (0.46) MAPTLMNAMEN1PLIN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 MAPT 4151/4885LMNA 3936/4885MEN1 2997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.